LTZ Therapeutics, a biotech startup focused on immunotherapy and situated in Shenzen, China and Redwood City, California, secured a Series A fundraising round of more than $20 million.
Leading this round, which increased total fundraising to almost $50 million, was newcomer Lapam Capital, with GL Ventures, K2 Venture Partners, and Shunwei Capital also participating.
The money will be used by the business to further the pipeline’s development for the treatment of autoimmune disorders and cancer using myeloid engager.
The money raised from the financing will be put towards quickening the pipeline’s development, assisting with the company’s Investigational New Drug (IND) procedure, and starting the Phase 1 clinical investigation of LTZ-301, the company’s main asset, as well as the work necessary to make LTZ-232, its second asset, IND-enabling.
Read also- Saudi-Arabia Based Intelmatix has Secured $20 Million in Series A Round Funding
LTZ Therapeutics intends to utilise the additional funds to enhance its workforce and pursue other research initiatives.
Under the direction of its founder and CEO, Robert Li, Ph.D., LTZ Therapeutics is a biotech business that specialises in immunotherapy and is working to enhance clinical outcomes for patients with autoimmune illnesses and cancer by developing new medicines using its innovative Myeloid Engager Platform.
Read also- India-Based EV charging startup ElectricPe has Secured $3 Million in Pre-Series A Round Funding
Based on reverse translational science and emerging disease biology of tumour microenvironment, LTZ is committed to developing immunotherapies capable of overcoming resistance and boosting anti-tumor immunity.
The company has main operations in Redwood City, California, and Shenzhen, China, with a team based in Heidelberg, Germany.
About LTZ Therapeutics
LTZ Therapeutics is a multinational biotech business developing immunotherapy treatments for oncology and autoimmune illnesses. Pioneering a novel myeloid engager platform based on reverse translational science, emerging disease biology, and the power of myeloid cell subsets, particularly macrophages, which have great potential as a therapy to improve patient lives and eliminate cancer.
